Skip to main content
SpringerLink
Log in

Therapeutic strategies for psychosis associated with alzheimer disease

  • Published:
Current Psychosis & Therapeutics Reports

Abstract

Psychotic disturbances in the context of Alzheimer disease are common and associated with poorer outcomes, decreased quality of life, increased institutionalization, and caregiver distress. Due to the unique nature of psychosis associated with dementia, standard measures of psychotic symptomatology may give an incomplete picture of clinical benefit. It is important to consider the impact of an agent on behavioral dyscontrol, especially agitation and aggression, as well as on psychotic symptoms. Challenges still remain in terms of defining the diagnosis and treatment of psychosis of Alzheimer disease with particular attention to adverse effects, drug-drug and drug-disease interactions, as well as underlying medical comorbidities and polypharmacy. New antipsychotics have replaced old ones as the treatment of choice, based on at least equal efficacy and superior safety and tolerability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tariot PN, Mack JL, Patterson MB,et al.:The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer’s Disease.Am J Psychiatry 1995,152:1349–1357.

    PubMed  CAS  Google Scholar 

  2. Lyketsos CG, Steinberg M, Tschanz JT,et al.:Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.Am J Psychiatry 2000,157:708–714.

    Article  PubMed  CAS  Google Scholar 

  3. Devanand DP, Jacobs DM, Tang MX,et al.:The course of psychopathologic features in mild to moderate Alzheimer disease.Arch Gen Psychiatry 1997,54:257–263.

    PubMed  CAS  Google Scholar 

  4. Jeste DV, Finkel SI:Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome.Am J Geriatr Psychiatry 2000,8:29–34.

    Article  PubMed  CAS  Google Scholar 

  5. Paulsen JS, Ready RE, Stout JC,et al.:Neurobehaviors and psychotic symptoms in Alzheimer’s disease.J Int Neuropsychol Soc 2000,6:815–820.

    Article  PubMed  CAS  Google Scholar 

  6. McShane R, Keene J, Gedling K,et al.:Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.BMJ 1997,314:266–270.

    PubMed  CAS  Google Scholar 

  7. Alexopoulos GS, Streim J, Carpenter D, Docherty JP:Using antipsychotic agents in older patients.J Clin Psychiatry 2004,65(Suppl 2):5–99; discussion 100–102; quiz 103–104.

    PubMed  Google Scholar 

  8. Schneider LS, Pollock VE, Lyness SA:A meta-analysis of controlled trials of neuroleptic treatment in dementia.J Am Geriatr Soc 1990,38:553–563.

    PubMed  CAS  Google Scholar 

  9. Lanctot KL, Best TS, Mittmann N,et al.:Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.J Clinic Psychiatry 1998,59:550–561.

    CAS  Google Scholar 

  10. Ballard C, Grace J, McKeith I, Holmes C:Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease.Lancet 1998,351:1032–1033.

    Article  PubMed  CAS  Google Scholar 

  11. Jeste DV, Caligiuri MP, Paulsen JS,et al.:Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.Arch Gen Psychiatry 1995,52:756–765.

    PubMed  CAS  Google Scholar 

  12. Devanand DP, Marder K, Michaels K,et al.:A randomized, placebo-controlled, dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease.Am J Psychiatry 1998,155:1512–1520.

    PubMed  CAS  Google Scholar 

  13. Porsteinsson AP, Ryan JM, Ismail MS, Tariot PN:Handbook of Dementia: Psychological, Neurological, and Psychiatric Perspectives. Edited by Lichtenberg PA, Murman DL, Mellow AM. Hoboken: John Wiley & Sons; 2003:335–357.

    Google Scholar 

  14. Katz IR, Jeste DV, Mintzer JE,et al.:Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.J Clin Psychiatry 1999,60:107–115.

    Article  PubMed  CAS  Google Scholar 

  15. De Deyn PP, Rabheru K, Rasmussen A,et al.:A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.Neurology 1999,53:946–955.

    PubMed  Google Scholar 

  16. Brodaty H, Ames D, Snowden JS,et al.:A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.J Clin Psychiatry 2003,64:134–143.

    Article  PubMed  CAS  Google Scholar 

  17. Medical Letter. Janssen Pharmaceutica, 2003.

  18. Satterlee WG, Reams SG, Burns PR,et al.:A clinical update in olanzapine treatment in schizophrenia and in elderly Alzheimer’s disease patients [abstract].Psychopharmacol Bull 1995,31:xx.

    Google Scholar 

  19. Street J, Clark WS, Gannon KS,et al.:Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s Disease in nursing care facilities: a double blind, randomized, placebo-controlled trial.Arch Gen Psychiatry 2000,57:968–976.

    Article  PubMed  CAS  Google Scholar 

  20. Clark WS, Street JS, Feldman PD, Brier A:The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s disease.J Clin Psychiatry 2001,62:34–40.

    Article  PubMed  CAS  Google Scholar 

  21. Medical Letter. Eli Lilly & Company, 2004.

  22. Tariot PN, Salzman C, Yeung PP,et al.:Long-Term use of quetiapine in elderly patients with psychotic disorders.Clin Ther 2000,22:1068–1084.

    Article  PubMed  CAS  Google Scholar 

  23. Tariot PN, Schneider LS, Katz IR,et al.:Quetiapine in nursing home residents with Alzheimer’s dementia and psychosis [poster abstract].Am J Geriatr Psychiatry 2002,10(Suppl 1):93.

    Google Scholar 

  24. Jeste DP, Peskind ER, Porsteinsson AP:Optimizing the management of psychosis in geriatric patients.17th annual meeting of the American Association for Geriatric Psychiatry: Baltimore; February 21–24, 2004.

  25. Jeste DV, Okamoto A, Napolitano J,et al.:Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.Am J Psychiatry 2000,157:1150–1155.

    Article  PubMed  CAS  Google Scholar 

  26. Jeste DV, Lacro JP, Bailey A,et al.:Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.J Am Geriatr Soc 1999,47:716–719.

    PubMed  CAS  Google Scholar 

  27. Schneider LS, Tariot PN, Lyketsos CG,et al.:National Institute of Mental Health clinical antipsychotic trial of intervention effectiveness (CATIE) — Alzheimer Disease trial methodology.Am J Geriatr Psychiatry 2001,9:346–360.

    Article  PubMed  CAS  Google Scholar 

  28. Cummings JL:Cholinesterase inhibitors: a new class of psychotropic compounds.Am J Psychiatry 2000,157:4–16.

    PubMed  CAS  Google Scholar 

  29. Feldman H, Gauthier S, Hecker J,et al., and the donepezil MSAD study investigators group:A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease.Neurology 2001,57:613–620.

    PubMed  CAS  Google Scholar 

  30. Tariot PN, Solomon PR, Morris JC,et al., and the Galantamine USA-10 Study Group:A 5-month, randomized placebo-controlled trial of galantamine in AD.Neurology 2000,54:2269–2276.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Monroe Community Hospital, 435 East Henrietta Road, 14620, Rochester, NY, USA

    Anton P. Porsteinsson MD

Authors
  1. Anton P. Porsteinsson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porsteinsson, A.P. Therapeutic strategies for psychosis associated with alzheimer disease. Current Psychosis & Therapeutics Reports 2, 116–120 (2004). https://doi.org/10.1007/BF02629431

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02629431

Keywords

Search

Navigation